Kinnate Biopharma Inc (KNTE)

Etorro trading 970x250
Kinnate Biopharma Inc (KNTE) Logo

About Kinnate Biopharma Inc

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. The company’s lead product candidate is KIN002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. Its other products in preclinical stage include KIN003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (FGFR)2 and FGFR3 genes; and small molecule research programs, including a Cyclin-Dependent Kinase 12 inhibitor in its KIN004 program. Kinnate Biopharma Inc. was founded in 2018 and is headquartered in San Diego, California. Address: 11975 El Camino Real, San Diego, CA, United States, 92130

Kinnate Biopharma Inc News and around…

Latest news about Kinnate Biopharma Inc (KNTE) common stock and company :

Kinnate Biopharma Inc. Details Two-Part Phase 1 Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
07 Oct, 2021 Yahoo! Finance

First in human, multicenter, non-randomized, open-label trial has expanded to three sites and is actively recruitingSAN FRANCISCO and SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, will be presenting design and rationale details of a Phase 1 trial (KN-8701: NCT04913285) evaluating KIN-2787 du

Kinnate Biopharma Inc. to Present Trial Design for its Lead RAF Kinase Inhibitor Program at the AACR-NCI-EORTC Virtual International Conference
30 Sep, 2021 FinancialContent

The KN-8701 trial is a multi-center, open-label, two-part trial of Kinnate’s lead RAF inhibitor candidate KIN-2787

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
27 Sep, 2021 FinancialContent

Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:SEEL) was changed from Neutral ...

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep, 2021 FinancialContent

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:WMG) from Equal-Weight to Overweight. ...

Kinnate Biopharma Inc. Presents Preclinical Data on its Lead FGFR Inhibitor Candidate at the JCA-AACR Precision Cancer Medicine International Conference
13 Sep, 2021 FinancialContent

KIN-3248 demonstrates highly-selective, potent, and broad-spectrum activity against mutations in both the FGFR2 and FGFR3 kinase domains – including acquired gatekeeper, molecular brake, and activation loop resistance mutations

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation
30 Aug, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results
16 Aug, 2021 FinancialContent
Should You Buy Kinnate Biopharma (KNTE) Ahead of Earnings?
12 Aug, 2021 Yahoo! Finance

Kinnate Biopharma (KNTE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
05 Aug, 2021 FinancialContent

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest ...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
04 Aug, 2021 FinancialContent

Wednesday's morning session saw 58 companies set new 52-week lows. Noteworthy Mentions: The company ...

The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Kinnate Biopharma Becomes Oversold (KNTE)
03 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Is Kinnate Biopharma Inc. (KNTE) A Good Stock To Buy?
28 Jul, 2021 Yahoo! Finance

In this article you are going to find out whether hedge funds think Kinnate Biopharma Inc. (NASDAQ:KNTE) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Kinnate Biopharma Inc. to Participate in the 2021 Wedbush PacGrow Healthcare Conference
27 Jul, 2021 FinancialContent
Analysts Forecast 18% Gains Ahead For The Holdings of PBSM
21 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $44.79 per unit.

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021
13 Jul, 2021 FinancialContent

Upgrades For Royal Dutch Shell PLC (NYSE:RDS), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first ...

Kinnate Biopharma Inc. to Participate in the William Blair Biotech Focus Conference 2021
07 Jul, 2021 FinancialContent
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors
28 Jun, 2021 FinancialContent

Accomplished immunologist and veteran biopharma executive has extensive experience in advancing pre-clinical stage oncology programs into the clinic

Analysts See 15% Upside For The Holdings of VBK
17 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $323.17 per unit.

Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires
07 Jun, 2021 FinancialContent
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
04 Jun, 2021 FinancialContent

Data highlights in vitro and in vivo activity of KIN-2787 against human cancers driven by Class I, Class II and Class III BRAF mutations

Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
25 May, 2021 FinancialContent
4 Biotech Stocks To Watch This Week
19 May, 2021 FinancialContent

Kinnate Biopharma Inc (KNTE) is a NASDAQ Common Stock listed in , ,

970x250